Pasotuxizumab (AMG-212)is a first-generation PSMA-targeting BiTEdesigned for PCa therapy.35 While AMG-212has shown some promise in a Phase I clinical trial, 90% of patientsdeveloped drug-neutralizing antibodies,35,36 thus necessitatingthe development of AMG-160, an advanced derivative of AMG-212, whichis currently under active investigation. Here, FOLH1 is linked to posterior cortical atrophy.